



Patent system of BRIC countries – challenges and opportunities from a Pharma perspective

Markus Gruber & Denis Barbier,
Principal Patent Attorneys, Novartis Pharma IP








Originator's Perspective

Our personal views

A Wish List for Patent Systems in BRIC countries



- IP plays an important role in providing the incentives necessary for the development and marketing of new medicines. An effective, transparent, and predictable IP system is necessary for both manufacturers of innovative medicines and manufacturers of generic medicines.
- Common international standards for patentability, patent examination and enforcement
- High quality patent examination leading to strong patents and a strong presumption of validity
- Stronger interaction of examiners and judges on international level
- Effective protection for clinical data
- Availability of effective enforcement system including PIs or patent linkage systems

		Pharma Patents Obtention	Pharma Patents Enforcement
BRAZIL		—	+
INDIA		—	—
RUSSIA		+	—
CHINA		+	(+)
SOUTH AFRICA		(+)	(+)

Thank you for your attention